Get More Information on Growth Hormone Deficiency Market - Request Sample Report
The Growth hormone deficiency market Size was valued at USD 5.48 billion in 2023 and is expected to reach USD 8.11 billion by 2031 and grow at a CAGR of 5.02% over the forecast period 2024-2031.
Demand for growth hormone deficiency (GHD) treatments worldwide is expected to expand at a considerable rate over the forecast period. That seems like quite the outlier, seeing how GHD was previously a rare disease affecting fewer than 1 in every 3,000-10,000 children per year nationally as per American Academy of Pediatrics, 2021 estimates. But this is creating a lucrative market growth opportunity.
It is indicated that GHD, in particular among adults with the disorder as well as patients of all ages who present to clinics for evaluation, is much more common than currently being recognized. A recent study in 2022 stated that by using diagnostic techniques with a higher sensitivity such as GHRH-pituitary stimulation tests, patients were diagnosed on average at an older age when compared to traditional methods. This suggests a higher yield when better diagnostics are used to detect previously uncaptured GHD cases. As diagnostics become more accurate, cheaper, and available in even remote areas of the world, we expect a rise of positive diagnoses for GHD that will increase the patient load needing treatment.
The increasing disposable income in emerging economies is another key driver. According to the World Bank, a number that would reach 3.2 billion globally by 2025 - many in emerging markets. These wages will grow by 4.7% this year in real terms, according to a report from the International Labour Organization (ILO) released in 2023 which says they are expanding at more than double the rate seen in developed economies as many poor nations recover faster and better from COVID-19 shocks compared with European countries or North America. As such, the increase in disposable incomes drives increased healthcare access for a broader patient base to receive GHD therapy within these nations. This trend, combined with advancements in diagnostics and therapeutics for GHD treatments will boost the market expansion during 2024-2031.
Other factors are the upgrade and development of new GHD formulations which is increasing the market. These improvements will increase patient adherence and treatment efficiency. For instance, long-acting formulations that reduce the number of injections would be a substantial advance in adherence rates among children. Moreover, these could ultimately lead to more patient-friendly formulations with reduced side-effects burden of treatment. These improvements are likely to increase the number of patients starting and remaining on treatment, thus boosting overall market growth for GHD therapies.
MARKET DYNAMICS:
KEY DRIVERS:
Growing awareness about growth hormone deficiency (GHD) and its treatments are the key drivers of this market.
The increasing prevalence of GHD is a key factor rationale for the growth in market size.
RESTRAINTS:
The side effects of synthetic growth hormone therapy are restraining the market.
High Price of Growth Hormone Replacement Therapy (GHD) is Restraining the overall market.
OPPORTUNITY:
Market growth will be driven by the development of novel GHD medications with improved side effect profiles during the forecast period.
Ongoing research and development (R&D) activities in the treatment of GHD provide a growth platform for this market.
KEY MARKET SEGMENTATION:
By Type
Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Others
As per type, Norditropin held the largest market share in 2023 owing to its prefilled pen system. Norditropin's user-friendly design makes it one of the preferred options for the treatment of growth hormone deficiency (GHD). It is a prefilled pen system that lessens the steps involved in traditional injection procedures such as vials and syringes. This innovation takes the hassle out of patients mixing and measuring their medication, while also potentially reducing errors, enhancing convenience, and promoting better patient adherence.
Prefilled pens offer accurate and predictable delivery of growth hormone necessary for stabilizing the levels of hormones in the body which is essential to treat it effectively With Norditropin's high level of clinical effectiveness and simplified administration, the product has become the standard for GHD in most markets, leading to significant commercial uptake and further expansion within this segment.
By Indication
Growth Hormone Deficiency
Turner Syndrome
Idiopathic Short Stature
Prader–Willi Syndrome
Small for Gestational Age
Others
In 2023, Growth Hormone Deficiency has accounted for a substantial market share in growth hormone therapy as the diagnostic criteria are more prevalent as compared to other indications such as Turner Syndrome or Prader-Willi Syndrome. Moreover, children with growth hormone deficiency require growth hormone therapy to attain normal height and development which is driving the need for growth hormones. There are now improved diagnostic capabilities and greater awareness in the diagnosis of growth hormone deficiency, which has resulted in an earlier detection and start of treatment. For example, the National Institutes of Health in the U.S. estimates that growth hormone deficiency affects between 1 child out of every 3500 to one child out of ten thousand This high prevalence highlights the large number of patients among whom growth hormone therapy is necessary.
Given the prominent position of growth hormone deficiency in the worldwide market for growth hormone therapy, pharmaceutical companies, and healthcare providers focus their investments on R&D efforts to meet consumer requirements. That is why the treatment of growth hormone deficiency brings considerable market revenues to both pharmaceuticals and endocrinology-related healthcare services. Hence, among all growth hormone therapy markets, Growth Hormone Deficiency (GHD) is the most diagnosed indication with a critical need for treatment in large patient populations and increased diagnostic abilities along with focused healthcare initiatives.
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Specialty Pharmacy
Growth hormone therapy is mainly distributed in four ways: hospital pharmacies, retail pharmacies, online channels, and specialized clinics. In 2023 Hospital Pharmacies held the highest market share. In other words, as awareness grows about the diagnosis and treatment of growth hormone deficiency (GHD), the majority of children receive their initial prescription for growth hormone while they are still inpatients that are in hospitals which is contributing to the largest share of the hospital segment.
Retail pharmacies are responsible for dispensing to patients with existing prescriptions that are contributing to the growth of this segment. Additionally, Online platforms have recently gained popularity, especially in Europe, the US as well as in emerging economies such as India including China. Now, these platforms are making the barriers to entry lower and offering growth hormone treatment through impulse purchases across a wider customer base.
Furthermore, Growth hormone treatment is also administered directly by specialized clinics (that focus on endocrinology or pediatrics) which is propelling the growth of this segment. However, there is potential for major changes in the growth hormone therapy distribution landscape, especially as digital platforms and regulations evolve.
Need any customization research on Growth Hormone Deficiency Market - Enquiry Now
REGIONAL ANALYSIS:
North America is leading the growth hormone market due to numerous factors. Public awareness campaigns in North America are throwing a light on growth hormone deficiency (GHD). This, coupled with educational programs for healthcare providers, has led to a significant improvement in identifying growth hormone deficiency. For instance, organizations such as the Magic Foundation and the Human Growth Foundation have periodically run awareness campaigns focusing on growth hormone deficiency (GHD). These campaigns typically aim to educate the public, healthcare providers, and policymakers about the symptoms, diagnosis, and treatment options for GHD. For detailed and up-to-date information, checking the websites or recent activities of these organizations would be advisable.
As a result, doctors are tracking growth hormone deficiency earlier in patients, allowing for faster treatment and potentially better outcomes. They support early detection which enables timely intervention and treatment. Early detection ensures that these children receive the growth hormone remedy they require.
However, established government reimbursement policies for growth hormone treatment (particularly in pediatric growth hormone deficiency cases) have also ensured the continuity of therapy which is another reason fuelling North America to leadership. This grants patients more access to this fundamentally much-needed treatment thanks to the financial aid from government programs. As an example, the US government Medicaid program provides growth hormone therapy coverage in select circumstances. That financial support ultimately results in market growth, since governments back producers. A strong foundation in healthcare, monitoring, and governmental support ensures that North America will remain the global leader in expansion for a better growth hormone market.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
KEY PLAYERS:
Major Players are Sandoz International GmbH (Novartis AG), EMD Serono Inc, Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Ipsen SA, Novo Nordisk AS, Teva Pharmaceutical Industries Ltd, AnkeBio Co. Ltd, Ferring BV, Pfizer Inc.
RECENT DEVELOPMENTS
In February 2022, Pfizer and OPKO received approval from Europe for a new growth hormone shot called NGENLA. This shot only needs to be administered once a week and it helps young children (from age 3) and teenagers whose bodies don't produce enough of their growth hormone to grow properly.
In October 2021, the US Food and Drug Administration approved a drug called Verzenio (abemaciclib) made by Eli Lilly. This medication is a treatment for a specific type of breast cancer in women - it's for high-risk, early-stage cancer that is positive for hormone receptors (HR+) but negative for another protein called HER2.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 5.48 Billion |
| Market Size by 2031 | US$ 8.11 Billion |
| CAGR | CAGR of 5.02 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope & Others) • By Indication (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader–Willi Syndrome, Small for Gestational Age & Others) • By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy & Specialty Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Sandoz International GmbH (Novartis AG), EMD Serono Inc, Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Ipsen SA, Novo Nordisk AS, Teva Pharmaceutical Industries Ltd, AnkeBio Co. Ltd, Ferring BV, Pfizer Inc. |
| Key Drivers | • Growing awareness about growth hormone deficiency (GHD) and its treatments are the key drivers of this market. • The increasing prevalence of GHD is a key factor rationale for the growth in market size. |
| RESTRAINTS | • The side effects of synthetic growth hormone therapy are restraining the market. • High Price of Growth Hormone Replacement Therapy (GHD) is Restraining the overall market. |
Ans: Growth Hormone Deficiency Market Size was valued at USD 5229.99 Million in 2022.
Ans: The Growth Hormone Deficiency Market is to grow at a CAGR of 4.9% over the forecast period 2023-2030.
Ans: North America region is dominating the Growth Hormone Deficiency Market.
The increased number of FDA approvals is also offering an opportunity for important businesses to create novel medications with fewer adverse effects.
Increase in the number of R&D activities.
Ans: The major players are Eli Lilly and Company, Roche, Ipsen, Ferring B.V., Novo Nordisk A/S, Pfizer, Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Novartis AG, Merck KGaA, and others.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Growth Hormone Deficiency Market Segmentation, By Type
7.1 Introduction
7.2 Norditropin
7.3 Genotropin
7.4 Humatrope
7.5 Saizen
7.6 Omnitrope
7.7 Others
8. Growth Hormone Deficiency Market Segmentation, By Indication
8.1 Introduction
8.2 Growth Hormone Deficiency
8.3 Turner Syndrome
8.4 Idiopathic Short Stature
8.5 Prader–Willi Syndrome
8.6 Small for Gestational Age
8.7 Others
9. Growth Hormone Deficiency Market Segmentation, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Retail Pharmacy
9.4 Online Pharmacy
9.5 Specialty Pharmacy
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 Trend Analysis
10.2.2 North America Growth Hormone Deficiency Market by Country
10.2.3 North America Growth Hormone Deficiency Market By Type
10.2.4 North America Growth Hormone Deficiency Market By Indication
10.2.5 North America Growth Hormone Deficiency Market By Distribution Channel
10.2.6 USA
10.2.6.1 USA Growth Hormone Deficiency Market By Type
10.2.6.2 USA Growth Hormone Deficiency Market By Indication
10.2.6.3 USA Growth Hormone Deficiency Market By Distribution Channel
10.2.7 Canada
10.2.7.1 Canada Growth Hormone Deficiency Market By Type
10.2.7.2 Canada Growth Hormone Deficiency Market By Indication
10.2.7.3 Canada Growth Hormone Deficiency Market By Distribution Channel
10.2.8 Mexico
10.2.8.1 Mexico Growth Hormone Deficiency Market By Type
10.2.8.2 Mexico Growth Hormone Deficiency Market By Indication
10.2.8.3 Mexico Growth Hormone Deficiency Market By Distribution Channel
10.3 Europe
10.3.1 Trend Analysis
10.3.2 Eastern Europe
10.3.2.1 Eastern Europe Growth Hormone Deficiency Market by Country
10.3.2.2 Eastern Europe Growth Hormone Deficiency Market By Type
10.3.2.3 Eastern Europe Growth Hormone Deficiency Market By Indication
10.3.2.4 Eastern Europe Growth Hormone Deficiency Market By Distribution Channel
10.3.2.5 Poland
10.3.2.5.1 Poland Growth Hormone Deficiency Market By Type
10.3.2.5.2 Poland Growth Hormone Deficiency Market By Indication
10.3.2.5.3 Poland Growth Hormone Deficiency Market By Distribution Channel
10.3.2.6 Romania
10.3.2.6.1 Romania Growth Hormone Deficiency Market By Type
10.3.2.6.2 Romania Growth Hormone Deficiency Market By Indication
10.3.2.6.4 Romania Growth Hormone Deficiency Market By Distribution Channel
10.3.2.7 Hungary
10.3.2.7.1 Hungary Growth Hormone Deficiency Market By Type
10.3.2.7.2 Hungary Growth Hormone Deficiency Market By Indication
10.3.2.7.3 Hungary Growth Hormone Deficiency Market By Distribution Channel
10.3.2.8 Turkey
10.3.2.8.1 Turkey Growth Hormone Deficiency Market By Type
10.3.2.8.2 Turkey Growth Hormone Deficiency Market By Indication
10.3.2.8.3 Turkey Growth Hormone Deficiency Market By Distribution Channel
10.3.2.9 Rest of Eastern Europe
10.3.2.9.1 Rest of Eastern Europe Growth Hormone Deficiency Market By Type
10.3.2.9.2 Rest of Eastern Europe Growth Hormone Deficiency Market By Indication
10.3.2.9.3 Rest of Eastern Europe Growth Hormone Deficiency Market By Distribution Channel
10.3.3 Western Europe
10.3.3.1 Western Europe Growth Hormone Deficiency Market by Country
10.3.3.2 Western Europe Growth Hormone Deficiency Market By Type
10.3.3.3 Western Europe Growth Hormone Deficiency Market By Indication
10.3.3.4 Western Europe Growth Hormone Deficiency Market By Distribution Channel
10.3.3.5 Germany
10.3.3.5.1 Germany Growth Hormone Deficiency Market By Type
10.3.3.5.2 Germany Growth Hormone Deficiency Market By Indication
10.3.3.5.3 Germany Growth Hormone Deficiency Market By Distribution Channel
10.3.3.6 France
10.3.3.6.1 France Growth Hormone Deficiency Market By Type
10.3.3.6.2 France Growth Hormone Deficiency Market By Indication
10.3.3.6.3 France Growth Hormone Deficiency Market By Distribution Channel
10.3.3.7 UK
10.3.3.7.1 UK Growth Hormone Deficiency Market By Type
10.3.3.7.2 UK Growth Hormone Deficiency Market By Indication
10.3.3.7.3 UK Growth Hormone Deficiency Market By Distribution Channel
10.3.3.8 Italy
10.3.3.8.1 Italy Growth Hormone Deficiency Market By Type
10.3.3.8.2 Italy Growth Hormone Deficiency Market By Indication
10.3.3.8.3 Italy Growth Hormone Deficiency Market By Distribution Channel
10.3.3.9 Spain
10.3.3.9.1 Spain Growth Hormone Deficiency Market By Type
10.3.3.9.2 Spain Growth Hormone Deficiency Market By Indication
10.3.3.9.3 Spain Growth Hormone Deficiency Market By Distribution Channel
10.3.3.10 Netherlands
10.3.3.10.1 Netherlands Growth Hormone Deficiency Market By Type
10.3.3.10.2 Netherlands Growth Hormone Deficiency Market By Indication
10.3.3.10.3 Netherlands Growth Hormone Deficiency Market By Distribution Channel
10.3.3.11 Switzerland
10.3.3.11.1 Switzerland Growth Hormone Deficiency Market By Type
10.3.3.11.2 Switzerland Growth Hormone Deficiency Market By Indication
10.3.3.11.3 Switzerland Growth Hormone Deficiency Market By Distribution Channel
10.3.3.12 Austria
10.3.3.12.1 Austria Growth Hormone Deficiency Market By Type
10.3.3.12.2 Austria Growth Hormone Deficiency Market By Indication
10.3.3.12.3 Austria Growth Hormone Deficiency Market By Distribution Channel
10.3.3.13 Rest of Western Europe
10.3.3.13.1 Rest of Western Europe Growth Hormone Deficiency Market By Type
10.3.3.13.2 Rest of Western Europe Growth Hormone Deficiency Market By Indication
10.3.3.13.3 Rest of Western Europe Growth Hormone Deficiency Market By Distribution Channel
10.4 Asia-Pacific
10.4.1 Trend Analysis
10.4.2 Asia-Pacific Growth Hormone Deficiency Market by Country
10.4.3 Asia-Pacific Growth Hormone Deficiency Market By Type
10.4.4 Asia-Pacific Growth Hormone Deficiency Market By Indication
10.4.5 Asia-Pacific Growth Hormone Deficiency Market By Distribution Channel
10.4.6 China
10.4.6.1 China Growth Hormone Deficiency Market By Type
10.4.6.2 China Growth Hormone Deficiency Market By Indication
10.4.6.3 China Growth Hormone Deficiency Market By Distribution Channel
10.4.7 India
10.4.7.1 India Growth Hormone Deficiency Market By Type
10.4.7.2 India Growth Hormone Deficiency Market By Indication
10.4.7.3 India Growth Hormone Deficiency Market By Distribution Channel
10.4.8 Japan
10.4.8.1 Japan Growth Hormone Deficiency Market By Type
10.4.8.2 Japan Growth Hormone Deficiency Market By Indication
10.4.8.3 Japan Growth Hormone Deficiency Market By Distribution Channel
10.4.9 South Korea
10.4.9.1 South Korea Growth Hormone Deficiency Market By Type
10.4.9.2 South Korea Growth Hormone Deficiency Market By Indication
10.4.9.3 South Korea Growth Hormone Deficiency Market By Distribution Channel
10.4.10 Vietnam
10.4.10.1 Vietnam Growth Hormone Deficiency Market By Type
10.4.10.2 Vietnam Growth Hormone Deficiency Market By Indication
10.4.10.3 Vietnam Growth Hormone Deficiency Market By Distribution Channel
10.4.11 Singapore
10.4.11.1 Singapore Growth Hormone Deficiency Market By Type
10.4.11.2 Singapore Growth Hormone Deficiency Market By Indication
10.4.11.3 Singapore Growth Hormone Deficiency Market By Distribution Channel
10.4.12 Australia
10.4.12.1 Australia Growth Hormone Deficiency Market By Type
10.4.12.2 Australia Growth Hormone Deficiency Market By Indication
10.4.12.3 Australia Growth Hormone Deficiency Market By Distribution Channel
10.4.13 Rest of Asia-Pacific
10.4.13.1 Rest of Asia-Pacific Growth Hormone Deficiency Market By Type
10.4.13.2 Rest of Asia-Pacific Growth Hormone Deficiency Market By Indication
10.4.13.3 Rest of Asia-Pacific Growth Hormone Deficiency Market By Distribution Channel
10.5 Middle East & Africa
10.5.1 Trend Analysis
10.5.2 Middle East
10.5.2.1 Middle East Growth Hormone Deficiency Market by Country
10.5.2.2 Middle East Growth Hormone Deficiency Market By Type
10.5.2.3 Middle East Growth Hormone Deficiency Market By Indication
10.5.2.4 Middle East Growth Hormone Deficiency Market By Distribution Channel
10.5.2.5 UAE
10.5.2.5.1 UAE Growth Hormone Deficiency Market By Type
10.5.2.5.2 UAE Growth Hormone Deficiency Market By Indication
10.5.2.5.3 UAE Growth Hormone Deficiency Market By Distribution Channel
10.5.2.6 Egypt
10.5.2.6.1 Egypt Growth Hormone Deficiency Market By Type
10.5.2.6.2 Egypt Growth Hormone Deficiency Market By Indication
10.5.2.6.3 Egypt Growth Hormone Deficiency Market By Distribution Channel
10.5.2.7 Saudi Arabia
10.5.2.7.1 Saudi Arabia Growth Hormone Deficiency Market By Type
10.5.2.7.2 Saudi Arabia Growth Hormone Deficiency Market By Indication
10.5.2.7.3 Saudi Arabia Growth Hormone Deficiency Market By Distribution Channel
10.5.2.8 Qatar
10.5.2.8.1 Qatar Growth Hormone Deficiency Market By Type
10.5.2.8.2 Qatar Growth Hormone Deficiency Market By Indication
10.5.2.8.3 Qatar Growth Hormone Deficiency Market By Distribution Channel
10.5.2.9 Rest of Middle East
10.5.2.9.1 Rest of Middle East Growth Hormone Deficiency Market By Type
10.5.2.9.2 Rest of Middle East Growth Hormone Deficiency Market By Indication
10.5.2.9.3 Rest of Middle East Growth Hormone Deficiency Market By Distribution Channel
10.5.3 Africa
10.5.3.1 Africa Growth Hormone Deficiency Market by Country
10.5.3.2 Africa Growth Hormone Deficiency Market By Type
10.5.3.3 Africa Growth Hormone Deficiency Market By Indication
10.5.3.4 Africa Growth Hormone Deficiency Market By Distribution Channel
10.5.3.5 Nigeria
10.5.3.5.1 Nigeria Growth Hormone Deficiency Market By Type
10.5.3.5.2 Nigeria Growth Hormone Deficiency Market By Indication
10.5.3.5.3 Nigeria Growth Hormone Deficiency Market By Distribution Channel
10.5.3.6 South Africa
10.5.3.6.1 South Africa Growth Hormone Deficiency Market By Type
10.5.3.6.2 South Africa Growth Hormone Deficiency Market By Indication
10.5.3.6.3 South Africa Growth Hormone Deficiency Market By Distribution Channel
10.5.3.7 Rest of Africa
10.5.3.7.1 Rest of Africa Growth Hormone Deficiency Market By Type
10.5.3.7.2 Rest of Africa Growth Hormone Deficiency Market By Indication
10.5.3.7.3 Rest of Africa Growth Hormone Deficiency Market By Distribution Channel
10.6 Latin America
10.6.1 Trend Analysis
10.6.2 Latin America Growth Hormone Deficiency Market by country
10.6.3 Latin America Growth Hormone Deficiency Market By Type
10.6.4 Latin America Growth Hormone Deficiency Market By Indication
10.6.5 Latin America Growth Hormone Deficiency Market By Distribution Channel
10.6.6 Brazil
10.6.6.1 Brazil Growth Hormone Deficiency Market By Type
10.6.6.2 Brazil Growth Hormone Deficiency Market By Indication
10.6.6.3 Brazil Growth Hormone Deficiency Market By Distribution Channel
10.6.7 Argentina
10.6.7.1 Argentina Growth Hormone Deficiency Market By Type
10.6.7.2 Argentina Growth Hormone Deficiency Market By Indication
10.6.7.3 Argentina Growth Hormone Deficiency Market By Distribution Channel
10.6.8 Colombia
10.6.8.1 Colombia Growth Hormone Deficiency Market By Type
10.6.8.2 Colombia Growth Hormone Deficiency Market By Indication
10.6.8.3 Colombia Growth Hormone Deficiency Market By Distribution Channel
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Growth Hormone Deficiency Market By Type
10.6.9.2 Rest of Latin America Growth Hormone Deficiency Market By Indication
10.6.9.3 Rest of Latin America Growth Hormone Deficiency Market By Distribution Channel
11. Company Profiles
11.1 Sandoz International GmbH (Novartis AG)
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 The SNS View
11.2 AnkeBio Co. Ltd.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 The SNS View
11.3 EMD Serono Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 The SNS View
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 The SNS View
11.5 F.Hoffmann-La Roche Ltd
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 The SNS View
11.6 Ipsen SA
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 The SNS View
11.7 Novo Nordisk AS
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 The SNS View
11.8 Teva Pharmaceutical Industries Ltd.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 The SNS View
11.9 Ferring BV
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 The SNS View
11.10 Pfizer Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Telehealth and Telemedicine Market Size was valued at USD 121 billion in 2023 and is expected to reach USD 818.87 billion by 2031 and grow at a CAGR of 27% over the forecast period 2024-2031.
The Orthopedic Software Market Size was assessed at USD 392.74 million in 2023, and is predicted to increase at a CAGR of 8.1 percent from 2024 to 2031, to reach USD 732.35 million.
The Blood Testing Market Size was valued at USD 98.3 billion in 2023 and is expected to reach USD 172.7 billion by 2031 and grow at a CAGR of 7.3% over the forecast period 2024-2031.
The Predictive Genetic Testing & Consumer/Wellness Genomics Market Size was valued at USD 2.2 billion in 2023, and is expected to reach USD 5.10 billion by 2031, and grow at a CAGR of 11.1% over the forecast period 2024-2031.
The Hearing Aids Market size was valued at USD 10.88 Billion in 2023 and is expected to reach USD 20.87 Billion By 2031 and grow at a CAGR of 8.5% over the forecast period of 2024-2031.
The Monoclonal Antibody Therapy Market size was valued at USD 87.8 Bn in 2023 and is expected to reach USD 230.38 Bn by 2031 with a growing CAGR of 12.8% Over the Forecast Period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
